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Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS
5132 in Combination with Carboplatin and Paclitaxel in
Patients with Previously Untreated, Advanced Non-small
Cell Lung Cancer
Panos Fidias, MD,* Nathan A. Pennell, MD, PhD,* Anthony L. Boral, MD, PhD,*
Geoffrey I. Shapiro, MD, PhD,† Arthur T. Skarin, MD,† Joseph P. Eder, Jr., MD,†
T. Jesse Kwoh, PhD,‡ Richard S. Geary, PhD,‡ Bruce E. Johnson, MD,† Thomas J. Lynch, MD,*
and Jeffrey G. Supko, PhD*
Background: A phase I trial was performed to evaluate the admin-
istration of carboplatin/paclitaxel in combination with ISIS-5132, a
phosphorothioate antisense oligodeoxynucleotide inhibitor of c-raf-1
kinase expression, in patients with advanced non-small cell lung cancer
(NSCLC).
Patients and Methods: Previously untreated patients with stage
IIIB/IV NSCLC received ISIS 5132 by continuous intravenous
infusion at 2.0 mg/kg/d for 14 days. Starting doses were paclitaxel
175 mg/m2 and carboplatin targeting an area under the free platinum
plasma concentration-time curve (AUCfp) of 5 mg  min/ml (dose
level 1). The carboplatin dose was then increased to AUCfp 6
mg  min/ml (dose level 2) after which the paclitaxel dose was
increased to 200 mg/m2 (dose level 3). The maximum tolerated dose
was established by toxicity during the first two 21-day cycles of
therapy. The pharmacokinetics of all three agents was determined
before and during the ISIS 5132 infusion.
Results: Thirteen patients were treated with the carboplatin/pacli-
taxel/ISIS 5132 combination. Dose-limiting neutropenia occurred in
two patients at dose level 3. Grade 3 and 4 nonhematologic toxicities
were infrequent and limited to nausea and constipation. The maxi-
mum tolerated doses were carboplatin AUCfp 6 mg  min/ml, pacli-
taxel 175 mg/m2, and ISIS 5132 2.0 mg/kg/d for 14 days. There
were no objective responses and the concurrent infusion of ISIS
5132 did not alter the plasma pharmacokinetics of paclitaxel or total
platinum.
Conclusion: ISIS 5132 can be safely combined with standard doses
of carboplatin and paclitaxel. Combining cytotoxic chemotherapeu-
tic agents with inhibitors of aberrant signal transduction mediated by
Raf proteins produced no objective responses in the dose and
schedule administered in this study.
Key Words: Chemotherapy, Clinical trials, Human subjects,
Pharmacokinetics.
(J Thorac Oncol. 2009;4: 1156–1162)
Non-small cell lung cancer (NSCLC) is the most frequentcause of cancer related deaths for both men and women
in the United States.1 The median survival time has been
prolonged with the use of platinum-based doublet chemother-
apy regimens in patients with advanced NSCLC; however,
the therapeutic gains have been modest and no regimen has
demonstrated clear superiority.2 The identification of new
compounds capable of inhibiting pathways critical to the
growth of malignant cells may be highly beneficial in the
treatment of advanced lung cancer.
The raf kinase gene family codes for serine/threonine
kinases that play a pivotal role in the mitogen-activated
protein kinase signaling pathway, which is critical to the
regulation of cell survival and proliferation.3 Aberrant signal-
ing through Raf proteins has been identified in a variety of
malignancies, including lung cancer, and Raf signaling has
been shown to be directly downstream of ras, an oncogene
mutated in 20% of NSCLC.4 Furthermore, activating raf gene
mutations have been shown to induce neoplastic transforma-
tion in NIH 3T3 cells in vitro and have been associated with
human tumors including melanoma, thyroid cancer, colorec-
tal cancer, and NSCLC.5,6
ISIS 5132 is a 20-base phosphorothioate antisense
oligodeoxynucleotide designed to hybridize to 3 untranslated
sequences of c-raf-1 mRNA. ISIS 5132 decreased c-raf-1
mRNA levels and Raf-1 protein synthesis in A549 lung
carcinoma cells in a sequence and concentration dependent
fashion, with an IC50 for inhibiting c-raf-1 mRNA in vitro
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between 50 and 100 nM.7 The dose needed to inhibit c-raf-1
expression in mouse tumor xenografts is approximately 10 to
20 mg/kg delivered by intravenous bolus injection.8 Three
different administration schedules have been evaluated in
phase I studies of ISIS 5132: a 2-hour intravenous infusion
given three times a week for 3 consecutive weeks9; a weekly
24-hour continuous intravenous infusion10; and a 21-day
continuous intravenous infusion repeated every 28 days.11
Weekly doses up to 24 mg/kg can be administered safely. A
maximum tolerated dose (MTD) was not identified for the
repeated short infusion schedule. Treatment related serious
adverse events, acute hemolytic anemia, and acute renal
failure occurred in two patients receiving 30 mg/kg of ISIS
5132 by the weekly 24-hour infusion schedule. When given
as more prolonged continuous infusion, delivering the drug at
rates up to 4 mg/kg/d for 21 days was tolerable, resulting in
the selection of this administration schedule for phase II
trials. Evidence of antitumor activity in the single agent phase
I trials included a partial response in a single patient with
advanced ovarian cancer treated with the 21-day continuous
infusion schedule, and prolonged stable disease in one patient
with pancreatic cancer, one colon cancer patient, and two
patients with renal cell cancer.
The use of carboplatin in combination with paclitaxel is
a well-established treatment for advanced NSCLC.2 Admin-
istering a 175 mg/m2 dose of paclitaxel as a 3-hour intrave-
nous infusion followed immediately by a 1-hour intravenous
infusion of carboplatin, dosed to achieve a target area under
the free platinum plasma concentration-time curve (AUCfp)
of 6 mg  min/ml, repeated every 21 days, has been previ-
ously described and provides similar therapeutic benefit as
other platinum-based regimens.12 In this report, we present
the results of a phase I trial to administer this particular
carboplatin/paclitaxel regimen in combination with ISIS 5132
given as a 14-day continuous intravenous infusion in patients
with previously untreated, advanced NSCLC. The duration of
the ISIS 5132 continuous infusion was shortened from 21 to
14 days with a 7-day rest period to align with the typical
21-day schedule used for carboplatin and paclitaxel. This
corresponds to a total dose of 28 mg/kg/cycle, which is
actually greater than the dose intensity (22.5 mg/kg/cycle)
that was previously shown to inhibit c-raf-1 mRNA in mRNA
derived from peripheral blood mononuclear cells during treat-
ment with the drug.9
The addition of ISIS 5132 to standard chemotherapy
has been examined in nude mice bearing subcutaneous xeno-
grafts of various human tumor models, including large cell
and squamous cell lung carcinomas.13 The majority of com-
binations resulted in an additive antitumor activity, whereas
treatment with ISIS 5132 in combination with cisplatin was
associated with a superadditive effect against small cell lung
cancer. A more recent study documented synergistic effects
when ISIS 5132 was given together with either carboplatin or
paclitaxel against tumors established from human ovarian
cancer cell lines.14 This preclinical evidence of synergism
with cytotoxic chemotherapy provided the rationale for the
current study.
The primary objective of the study was to determine the
maximum doses of paclitaxel and carboplatin that are toler-
ated by patients when given together with ISIS 5132 and
infused at a rate of 2.0 mg/kg/d for 14 days. The secondary
objectives included characterizing the toxicity profile of the
regimen, a preliminary assessment of antitumor activity, and
determining whether the concurrent administration of ISIS 5132
alters the plasma pharmacokinetics of either paclitaxel or carbo-
platin. No specific biomarkers were evaluated in this trial.
PATIENTS AND METHODS
Patient Selection
Patients with histologically confirmed, advanced NSCLC,
as defined by the American Joint Committee on Cancer classi-
fication system as stage IIIB with malignant pleural/pericardial
effusion or stage IV, who have not been previously treated with
chemotherapy were eligible for this study. The eligibility criteria
for the study included age 18 years, Eastern Cooperative
Oncology Group performance status of 0–2, radiographically
measurable tumor by World Health Organization criteria, ac-
ceptable hematologic (absolute neutrophil count1500 cells/l,
platelet count 100,000/L, hemoglobin 9.0 g/dl, normal
prothrombin time, and partial thromboplastin time), hepatic
(serum aspartate aminotransferase and alkaline phosphatase
concentrations 2.5 times the upper limit of normal, total
bilirubin 1.5 mg/dl), and renal (serum creatinine 1.5
mg/dl) function. Prior radiation therapy had to be completed
at least 4 weeks before entry into the study. Conditions
resulting in exclusion from the study included brain metas-
tases other than locally treatable lesions and concurrent an-
ticoagulation therapy because of the potential for ISIS 5132
to prolong coagulation times. The protocol for this clinical
trial was approved by the Dana-Farber/Harvard Cancer Cen-
ter (Boston, MA) Scientific Review Committee and Institu-
tional Review Board. Patients signed a written informed
consent document satisfying all institutional, state, and fed-
eral requirements as a condition of registration into the study.
Drug Administration
Paclitaxel and carboplatin (Bristol-Meyers Squibb Co.,
Princeton, NJ) were obtained from commercial sources as the
standard dosage form for injection. ISIS 5132 was supplied
by ISIS Pharmaceuticals, Inc. (Carlsbad, CA) as a sterile 10
mg/ml solution for intravenous administration in phosphate
buffered saline. The volume of this solution providing the
amount of drug to be given over 7 days was diluted with
normal saline for injection, to a total volume of 250 ml. A
programmable ambulatory infusion pump with an extension
set fitted with a 0.22-m in-line filter was used to deliver the
dosing solution through a central venous catheter at a rate of
1.5 ml/h. Freshly prepared dosing solution and a new exten-
sion set were placed in the pump after 168 hours.
ISIS 5132 was administered as a continuous intrave-
nous infusion through an implanted catheter for 14 days
beginning 96 hours before the administration of paclitaxel/
carboplatin, except for the first cycle of therapy, in which the
infusion was delayed until 48 hours after starting the pacli-
taxel infusion to accommodate the pharmacokinetic drug
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interaction studies. Before the administration of paclitaxel, all
patients received a standard premedication regimen consist-
ing of dexamethasone, diphenhydramine, and a histamine
H2-receptor antagonist to prevent hypersensitivity reactions
to Cremophor EL in the paclitaxel vehicle, as well as a 5-HT3
receptor antagonist antiemetic. Paclitaxel was administered
by intravenous infusion over 3 hours after which carboplatin
was given as a 1-hour intravenous infusion. Individualized
doses of carboplatin to provide a target AUCfp were based on
the Calvert formula, using the Cockroft-Gault equation to
calculate creatinine clearance.15
Treatment with the same dose of each drug was re-
peated every 21 days, for a maximum of 8 cycles, for patients
who did not experience a dose limiting toxicity (DLT), as
defined below, if all eligibility requirements continued to be
satisfied. Treatment with any other approved or investiga-
tional chemotherapeutic agent or radiation was not permitted.
Granulocyte colony stimulating factor was not used routinely
but could be used at the discretion of the treating physician if
clinically indicated. Therapy was discontinued for any of the
following reasons: progressive disease, life-threatening tox-
icity, incomplete recovery from toxicity, physician decision
in consideration of other medical conditions, patient request,
or noncompliance with the protocol.
Dose Escalation
A summary of the dose escalation plan is detailed in
Table 1. ISIS 5132 was infused at a rate of 2.0 mg/kg/d to all
patients. The starting dose of paclitaxel was 175 mg/m2 in
combination with carboplatin at an AUCfp of 5 mg  min/ml
(dose level 1). Subsequently, the carboplatin dose was in-
creased to an AUCfp of 6 mg  min/ml with paclitaxel main-
tained at 175 mg/m2 (dose level 2), after which the paclitaxel
dose was increased to 200 mg/m2 (dose level 3). The MTD
was established by the occurrence of DLTs during the first
two 21-day cycles of therapy. Patients receiving any fraction
of the ISIS 5132 dose were considered to be evaluable for
toxicity assessments. The National Cancer Institute Common
Toxicity Criteria version 2.0 (available at: http://ctep.cancer.
gov/-forms/-ctcv2nom-4-30-99-final3.pdf) was used to cate-
gorize and grade toxicities. DLT was defined as any of the
following adverse events: (a) grade 4 neutropenia for 3
days or associated with fever; (b) grade 4 thrombocytopenia;
(c) grade 3 thrombocytopenia with clinically evident bleed-
ing; (d) grade 4 coagulation abnormality if associated with
grade 2 hemorrhage; (e) grade 4 nausea and/or vomiting
despite maximum antiemetic premedication; and (f) any non-
hematological toxicities of grade 3.
Groups of three patients were initially treated at each
dose level. Escalation of the dose to the next scheduled level
proceeded if there were no DLTs in any of the patients
entered into the current dose level within 21 days after
treatment. An additional three patients were entered into a
given dose level in cases where a single patient experienced
a DLT. Dose escalation proceeded in the absence of a DLT in
these additional patients. The occurrence of a DLT in at least
two patients from any cohort of three to six patients estab-
lished the preceding dose level as the MTD.
Patient Evaluations
Preliminary evaluations performed within 14 days of
beginning treatment in the study included a medical history,
physical and neurologic examinations, performance status
determination, electrocardiogram, chest radiograph, complete
blood count (CBC) with platelet and differential counts,
coagulation tests (prothrombin time, partial thromboplastin
time), standard serum chemistry profile with electrolyte mea-
surements, urinalysis, pregnancy test for women of child-
bearing potential, and radiographic tumor measurement.
Evaluations on days 0 and 16 of treatment included a physical
examination, determination of performance status, adverse
event assessment, as well as evaluation of CBC, coagulation
tests, and serum chemistries. Physical examination, perfor-
mance status, adverse event evaluation, and CBC were also
checked on days 1 and 9.
Response was based on changes in the sum of the
largest diameter of target tumor lesions determined by uni-
dimensional measurement.16 A baseline assessment of mea-
surable disease by computed tomography was performed
within 2 weeks of beginning therapy. Evaluations to assess
therapeutic response were performed after completing every
second cycle of therapy until relapse or death. Complete
response was defined as the complete disappearance of all of
the clinical and radiologic evidence of tumor for 28 days as
confirmed by a second measurement, including being free of
all of the tumor-related symptoms. Partial response was de-
fined as a 50% or greater decrease in the sum of all of the
measurable lesions for 28 days. Stable disease was defined as
the absence of either a response or progressive disease. Progres-
sive disease was an unequivocal increase of at least 25% in the
overall sum of the measurable lesions compared with baseline or
the appearance of new lesions. The duration of a response was
measured from the date that the response was first recorded to
the date of documented disease progression.
Pharmacokinetic Studies
Samples to define the plasma concentration-time pro-
files of paclitaxel and total platinum during the first and
second cycles of therapy were obtained shortly before dosing
and at the following times relative to the beginning of the
paclitaxel infusion: 10 minutes, 1.5, 3.0, 3.25, 4.0, 4.25, 4.5,
5.0, 5.5, 6.0, 7.0, 8.0, 28, and 48 hours. The samples desig-
nated for collection at 3.0 hours and 4.0 hours were drawn
several minutes before the end of the paclitaxel and carbo-
platin infusions, respectively. At each time point, blood (10
ml) was drawn from a peripheral vein in the arm not used for
infusing the drugs into a collection tube with freeze-dried
sodium heparin. During the second cycle of therapy, addi-
tional blood samples (2 ml) were collected in tubes contain-
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ing potassium-ethylenediaminetetraacetic acid for determining
the concentration of ISIS 5132 in plasma 24 hours after the start
of the infusion, on day 4 before, during and after the adminis-
tration of paclitaxel and carboplatin, and on days 5, 6, 7, and 14.
The blood samples were promptly centrifuged for 10 minutes at
2500 g and 4°C, upon which the plasma was transferred into
polypropylene cryovials and stored at 70°C.
The concentrations of paclitaxel and total platinum
were measured in plasma using analytical methods that have
been previously reported.17,18 The analytical method for pac-
litaxel involved isocratic reversed-phase high performance
liquid chromatography with automated column switching and
ultraviolet detection. The concentration of total platinum was
determined by flameless atomic absorption spectrophotome-
try. The lower limits of quantitation of the assays were 5
ng/ml (6 nM) for paclitaxel and 0.5 M for total platinum.
The concentration of full-length ISIS 5132 was determined
by capillary gel electrophoresis by ClinTrial Bio-Research,
Ltd. (Quebec, Canada), as previously reported.9 Between-day
accuracy for the analysis of quality control samples of each
analyte in human plasma was within 15% of the know
concentrations, with a precision 15%.
Actual sample times were calculated from the begin-
ning of the paclitaxel and carboplatin infusions to the mid-
point of the sample collection interval. Plasma concentration-
time curves for individual patients were analyzed by standard
noncompartmental methods using WinNonlin Professional
5.0 software (Pharsight Corp., Cary, NC).19 Area under the
plasma concentration-time curve from time zero to infinity
(AUC) was estimated using the logarithmic-linear trapezoidal
algorithm to the last data point, with extrapolation to time
infinity using the estimated value of the slope of the terminal
logarithmic-linear data. Pharmacokinetic parameters esti-
mated by the program included: total body clearance, half-life
of the terminal disposition phase (t1/2,z), mean residence time,
and the apparent volume of distribution at steady state (Vss).
The steady-state concentration (C ss) of ISIS 5132 in plasma
was calculated for each patient as the geometric mean of the
determinations for all samples obtained during infusion of the
drug. Mean values of the pharmacokinetic variables for each
treatment group were calculated as the geometric mean of the
individual patient values, and the standard deviation was
estimated by the Jacknife method.20–22 Mean pharmacoki-
netic parameters for paclitaxel and total platinum when given
alone or together with ISIS 5132 to the same group of patients
were statistically compared using the paired two-tailed t test
after logarithmic transformation of the data, with p  0.05
considered to be significantly different.
RESULTS
Patient Characteristics
A total of 13 patients with stage IV disease, adenocar-
cinoma histology, and an Eastern Cooperative Oncology
Group performance status of 0 or 1 were enrolled in the study
and treated. The group was comprised of four men (31%) and
nine women (69%) with a median age of 52 years (range,
34–75 years).
Maximum Tolerated Dose
There were no DLTs experienced by the four patients
enrolled for treatment in dose level 1 or the initial three
patients in dose level 2. At the third dose level of paclitaxel
200 mg/m2 and carboplatin at an AUCfp of 6 mg  min/ml,
two of three patients had dose-limiting neutropenia and/or
febrile neutropenia. The first patient experienced grade 4
neutropenia on day 16 of cycle 1, which lasted for longer than
72 hours and necessitated a dose reduction for the next cycle.
The second patient was hospitalized for a fever and catheter-
related infection in the setting of grade 4 neutropenia during
cycle 2 and was subsequently removed from the study for
disease progression. An additional three patients were then
enrolled for treatment with the second dose level to confirm
safety at this dose level, thus defining carboplatin AUCfp 6
mg  min/ml, paclitaxel 175 mg/m2, ISIS 5132 2 mg/kg/d for
14 days as the MTD for this regimen. Although no patients in
dose level 2 were designated as experiencing a DLT, one
patient was hospitalized with a peripherally-inserted central
venous catheter infection that was not attributed to study
treatment in the setting of grade 4 neutropenia that did not in
itself meet criteria for a DLT. The infected catheter was
removed and replaced once the patient recovered, and the
patient went on to receive six cycles of study treatment.
Toxicity
A total of 44 cycles of carboplatin, paclitaxel, and ISIS
5132 were given to 13 patients, with a median number of
three cycles and a maximum of six cycles delivered. All
toxicities that were at least possibly attributable to the study
treatment are indicated in Table 2. Overall, the toxicities were
mild and the treatment was well tolerated at dose levels 1 and
2. Ten of 13 patients (77%) experienced hematologic toxic-
ities greater than or equal to grade 2, although only three
patients (23%) experienced grade 2 or greater nonhemato-
logic toxicities. All three patients were in dose level 3, and
these toxicities included grade 2 fatigue (n  1), grade 2
myalgia (n  2), grade 3 constipation (n  1), and grade 3
nausea (n  1).
TABLE 2. Summary of Clinical Toxicities
No. of Patients with Grade 2/3/4
Toxicitya
Dose Level 1 2 3
Anemia 3/0/0 2/1/0 2/0/0
Thrombocytopenia 1/0/0 1/0/0 0/1/0
Neutropenia 0/0/4 1/1/2 1/0/2b
Febrile neutropenia 0/0/0 0/0/0 0/0/1b
Constipation 0/0/0 0/0/0 0/1/0
Nausea 0/0/0 0/0/0 0/1/0
Fatigue 0/0/0 0/0/0 1/0/0
Myalgia/arthralgia 0/0/0 0/0/0 2/0/0
Increased creatinine 0/0/0 0/0/0 1/0/0
a Highest grade of each categorical toxicity experienced by each patient during all
cycles of therapy.
b Dose limiting toxicities that occurred during the first two cycles of therapy.
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Response
All 13 patients were evaluable for response. No com-
plete or partial responses were seen. Nine patients (69%) had
stable disease as their best response, with a median of five
cycles delivered (range, 3–6). Four patients (31%) had pro-
gressive disease as their best response after a median of two
cycles (range, 1–2). Overall survival time was 6.9 months
with a 46% 1-year survival rate. Three patients received
salvage therapy consisting of gemcitabine for two patients
and docetaxel for the other. All the patients enrolled into the
study are deceased.
Pharmacokinetics
Pharmacokinetic data obtained from the 10 patients
evaluated in dose levels 1 and 2 who received the two initial
cycles of therapy was statistically compared to assess the
influence of the concurrent infusion of ISIS 5132 on the
disposition of paclitaxel and carboplatin. Each of these pa-
tients received 175 mg/m2 of paclitaxel given as a 3-hour
infusion in combination with carboplatin dosed to provide a
target AUCfp of 5 or 6 mg  min/ml. Data from the three
patients receiving paclitaxel 200 mg/m2 in dose level 3 was
excluded from the statistical analysis because the drug exhib-
its dose- and schedule-dependent pharmacokinetics, whereas
carboplatin exhibits linear pharmacokinetics for the range of
doses administered in this study.23,24 Mean values of phar-
macokinetic parameters for paclitaxel and total platinum for
this group of patients are presented in Table 3, together with
results from the statistical comparisons. The mean pharma-
cokinetic data for both drugs when given before initiating the
infusion of ISIS 5132 in cycle 1 were in excellent agreement
with historical data from the literature.24,25 Data on the
steady-state pharmacokinetics of ISIS 5132 during cycle 2
were available for seven of the patients. The overall mean 
SD Css for the full-length oligodeoxynucleotide, 0.65  0.20
g/ml, was in excellent agreement with previously reported
data from cancer patients who were treated with single agent
ISIS 5132 at an infusion rate of 2.0 mg/kg/d.26,27 Differences
between the mean pharmacokinetic parameters in cycles 1
and 2, when paclitaxel and carboplatin were given 72 hours
after beginning the continuous infusion of ISIS 5132 at a rate
of 2.0 mg/kg/d, were relatively small, ranging from 7.7% to
16.2%. There were no differences between any parameters
that approached statistical significance. These findings sug-
gest that the concurrent administration of ISIS 5132 had no
discernable effect on the plasma pharmacokinetics of pacli-
taxel or total platinum.
DISCUSSION
This is the first report of a clinical trial to evaluate the
administration of a raf kinase antisense oligodeoxynucleotide
in combination with standard chemotherapy in the treatment
of lung cancer. We have shown that therapeutic doses of
carboplatin and paclitaxel can be safely delivered in combi-
nation with a prolonged continuous infusion of ISIS 5132
without affecting the pharmacokinetic behavior of either
carboplatin or paclitaxel. The toxicities observed were those
expected based on the side-effect profile of the agents used.
In contrast to the study of prolonged infusion ISIS 5132 as
monotherapy, for which infusion rates up to 4.0 mg/kg/d did
not elicit DLT,11 dose-limiting neutropenia was identified at
the 2.0 mg/kg/d dose level when the oligonucleotide was
combined with standard doses of carboplatin and paclitaxel.
Hematologic toxicity, specifically neutropenia, prevented es-
calation beyond an AUCfp of 6 mg  min/ml for carboplatin
and a paclitaxel dose of 175 mg/m2. These doses are some-
what lower than those achieved in several other phase I
studies of these agents when used as a doublet combination.
Rowinsky et al. were able to escalate carboplatin to an AUCfp
of 7 mg  min/ml with paclitaxel 225 mg/m2 given as a 3-hour
infusion, whereas Natale et al. recommended a phase II
dose of carboplatin at an AUCfp of 6 mg  min/ml in
combination with paclitaxel at 225 mg/m2.28,29 Neverthe-
TABLE 3. Mean Pharmacokinetic Parameters of Paclitaxel and Total Platinum Determined Before
and During the Infusion of ISIS 5132
Drug Parameter Concurrent ISIS 5132 Mean  SDa Difference (%) P
Paclitaxel CL (l/h/m2)  11.1  2.7 12.6 0.39
 12.5  4.2
Vss (l/m
2)  78.2  40.6 16.2 0.48
 90.9  35.7
t1/2,z (h)  11.9  3.9 9.2 0.62
 13.0  6.3
Carboplatinb CL (l/h/m2)  2.22  0.53 7.7 0.44
 2.05  0.38
Vss (l/m
2)  16.6  6.8 10.8 0.53
 18.4  5.2
t1/2,z (h)  7.55  2.26 9.3 0.43
 8.25  1.24
Pharmacokinetic data for the group of 10 patients who received paclitaxel 175 mg/m2 in combination with carboplatin at a target AUCfp of
5 or 6 mg  min/ml.
a Geometric mean  SD estimated by the Jacknife method.
b Carboplatin pharmacokinetic parameters were based on the total platinum concentration in plasma.
CL, total body clearance; Vss, steady-state apparent volume of distribution; t1/2,z, half-life of the apparent terminal disposition phase.
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less, there appears to be no significant dose-response effect
for paclitaxel in NSCLC and many investigators use a dose
of 175 mg/m2 infused over 3-hour as a standard of care.30–34
Therefore, we believe that this study demonstrates that clin-
ically relevant doses of carboplatin and paclitaxel can be
delivered together with ISIS 5132. Moreover, phosphorothio-
ate-specific toxicities, such as hemolytic anemia and comple-
ment activation, were not observed in this study, suggesting
that other oligonucleotides of the same class could be safely
delivered in combination with this regimen.
The absence of any indications of a therapeutic benefit
in this cohort of previously untreated patients with a good
performance status was disappointing, with no clinical re-
sponses and a median survival of only 6.9 months. The
efficacy of single agent ISIS 5132 has been evaluated in four
disease-specific phase II clinical trials involving patients with
advanced prostate cancer, colorectal cancer, ovarian cancer,
and NSCLC.26,27,35,36 Although no objective responses were
documented in any of these studies, stable disease was re-
ported at rates ranging from 13% in patients with NSCLC to
33% in patients with colorectal cancer.
The pharmacokinetics of paclitaxel and carboplatin
were not affected when the two drugs were given concur-
rently with ISIS 5132 in the current study, but the lack of
observed responses raises the question of an unfavorable
pharmacodynamic interaction between the oligonucleotide
and chemotherapy. In support of this hypothesis, Torres et
al.37 reported on the importance of Raf-1 in paclitaxel-
induced cell death and suggested that terminal mitotic arrest
occurs through a Raf-1 dependent pathway. Nevertheless, in
vitro studies have shown additive or even synergistic antitu-
mor activity when ISIS 5132 was combined with a variety of
chemotherapeutic agents.14,15 Additionally, Rasouli-Nia et
al.38 evaluated the relationship of Raf-1 kinase activity and de
novo paclitaxel resistance in human cervical tumors and
found that Raf-1 kinase suppressed paclitaxel-induced apo-
ptosis. Down regulation of this activity with an antisense
construct resulted in a fourfold increase in paclitaxel-induced
cytotoxicity.
The lack of antitumor activity does not appear to be an
oligonucleotide class effect, as illustrated by the phase I/II
trial in advanced NSCLC patients using a similar compound,
the anti-PKC- oligonucleotide ISIS 3152. A response rate of
36% was reported for this study in which ISIS 3152 was
given in combination with cisplatin and gemcitabine.39 A
potential explanation is that the very small number of patients
in our study accounts for the inability to demonstrate clinical
activity. The 95% confidence intervals of a response rate of
0% in 13 patients are broad (0–20%) and overlap with
published response rates (17%) for the combination of
paclitaxel and carboplatin in advanced lung cancer.2 Al-
though larger studies would be needed to investigate this
further, there are presently no plans to pursue the develop-
ment of ISIS 5132 further in NSCLC patients. Nevertheless,
the MAP kinase pathway remains a promising target in
NSCLC, and there are a number of new compounds targeting
Raf in various stages of clinical development. The liposome-
encapsulated antisense oligonucleotide LErafAON, which
also targets c-raf-1 kinase, has completed phase I trials.40,41 In
addition to antisense oligonucleotides, small molecule ty-
rosine kinase inhibitors of Raf such as sorafenib, the pan-Raf
inhibitor Raf265 (Novartis International AG, Switzerland),
and the mutant B-Raf inhibitor PLX4032 (F. Hoffmann-La
Roche AG, Switzerland/Plexxikon Inc, California) are being
evaluated.42–45 Among these agents, sorafenib has undergone
the most extensive clinical evaluation. It has been safely com-
bined with carboplatin and paclitaxel in phase I trials,46,47 and a
randomized phase III trial of carboplatin and paclitaxel with or
without sorafenib in advanced NSCLC patients was recently
initiated. Unfortunately, this study was recently terminated at the
first evaluation point when the data monitoring committee de-
termined that it was unlikely to meet its primary end point of
improved survival.48 Further studies will be needed to define the
role of Raf inhibition in the treatment of NSCLC.
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